Skip to main content

Indaptus Therapeutics, Inc.

corporate_fare Company Profile

Indaptus Therapeutics, Inc.

INDP·NASDAQ·Healthcare·CIK 0001857044

Indaptus Therapeutics, Inc. is a clinical biotechnology company focused on developing immunotherapy products to combat cancer and viral infections. Its primary product in development is Decoy20. This candidate is designed to be used either alone or in combination with other therapies to achieve lasting responses in various conditions. These include lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infections. Decoy20 is also being developed for the treatment of advanced solid tumors. The company, which was previously known as Intec Parent, Inc., adopted the name Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is based in New York, New York.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) is a publicly traded company in the Healthcare sector. Wiseek monitors INDP SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Indaptus Therapeutics Reports Critical Cash Shortage, Massive Dilution, and Halted Clinical Programs
  • Indaptus Therapeutics Reports Critical Cash Shortage, Less Than One Month of Operating Funds Remaining
  • Cash Dwindles to $1.5M for Indaptus Therapeutics, Warns of Financing Uncertainty
  • Major Investors Disband Group Formed During Recent Dilutive Financing
  • Indaptus Therapeutics Appoints Two Independent Directors, Bolstering Financial and IP Expertise

monitoring Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$20.85M
Diluted EPS
-$21.58
Op. Cash Flow
-$14.82M
Operating Income
-$19.83M
Cash & Equivalents
$8.51M
Debt / Equity
0.00×
Shares Outstanding
2.17M sh
Source: 10-K · filed 2026-03-17 · accession 0001493152-26-010585

supervised_user_circle Insider Transactions

  • 2026-03-23 Lazar David E. Director
    Open-market sale 896.8K sh 2 fills derivative
  • 2026-02-26 Jabbour Jerome D Director
    Grant/Award 25K sh derivative
  • 2026-02-11 Meckler Jeffrey A Co-Chief Executive Officer Officer · Director
    Grant/Award 16.69K sh 3 fills derivative
  • 2026-01-20 Ben-Tzvi Avraham Director
    Grant/Award 25K sh
  • 2026-01-07 NATAN DAVID Director
    Grant/Award 25K sh derivative
  • 2025-12-23 Ben-Tzvi Avraham Director
    Grant/Award 25K sh derivative
  • 2025-12-22 Meckler Jeffrey A Co-Chief Executive Officer Officer · Director · 10% Owner
    Grant/Award 216.62K sh $439.73K @ $2.03
  • 2025-12-22 Linscott Walt Addison Chief Operating Officer Officer
    Grant/Award 54.42K sh $110.47K @ $2.03
  • 2025-12-22 Sassi Nir Chief Financial Officer Officer
    Grant/Award 26.76K sh $54.32K @ $2.03
  • 2025-12-22 Newman Michael James CSO and Director Officer · Director
    Grant/Award 52.2K sh $105.97K @ $2.03
  • 2025-07-27 Meckler Jeffrey A Chief Executive Officer Officer · Director
    Grant/Award 6.07K sh $50.38K @ $8.30
  • 2025-07-27 Meckler Jeffrey A Chief Executive Officer Officer · Director
    Grant/Award 12.14K sh $100.76K @ $8.30 derivative
  • 2025-06-10 Hayes William B Director
    Grant/Award 12.5K sh derivative
  • 2025-06-10 Martell Robert Director
    Grant/Award 12.5K sh derivative
  • 2025-06-10 MADDALUNA ANTHONY J Director
    Grant/Award 12.5K sh derivative
  • 2025-06-10 Pomerantz Roger Director
    Grant/Award 30K sh derivative
  • 2025-06-10 Karah Hila Director
    Grant/Award 12.5K sh derivative
  • 2025-06-10 Gilbert Mark John Director
    Grant/Award 12.5K sh derivative
  • 2026-02-11 Meckler Jeffrey A Co-Chief Executive Officer Officer · Director
    Non-cash transfer 16.69K sh 3 fills derivative
From SEC Form 4 + 5 (insider beneficial-ownership filings) · last 12 months · view all on SEC EDGAR ↑
$1.09 +0.03% today
52-week range $1.51 – $19.91
Market cap
$120.04M
Volume
178.1K (2.1× avg)
3-mo avg 85.1K
Price snapshot as of 2026-05-22 01:52 UTC (Market snapshot (OVERNIGHT))

show_chartPrice Chart

Loading chart...

feed INDP - Latest Insights

INDP
May 15, 2026, 8:15 AM EDT
Filing Type: 10-Q
Importance Score:
9
INDP
May 15, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
INDP
May 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
INDP
Apr 29, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
INDP
Apr 22, 2026, 9:59 PM EDT
Filing Type: 8-K
Importance Score:
7
INDP
Apr 03, 2026, 12:00 PM EDT
Filing Type: 8-K
Importance Score:
8
INDP
Mar 30, 2026, 9:46 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
INDP
Mar 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
10
INDP
Mar 24, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
INDP
Mar 24, 2026, 4:02 PM EDT
Filing Type: 4
Importance Score:
8
INDP
Mar 17, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
INDP
Mar 02, 2026, 5:20 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
10
INDP
Feb 27, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
INDP
Feb 12, 2026, 9:30 AM EST
Filing Type: 8-K
Importance Score:
9
INDP
Feb 12, 2026, 9:30 AM EST
Filing Type: DEFA14A
Importance Score:
9
INDP
Jan 21, 2026, 5:21 PM EST
Filing Type: DEF 14A
Importance Score:
10
INDP
Jan 20, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8
INDP
Jan 08, 2026, 5:26 PM EST
Filing Type: 8-K
Importance Score:
7
INDP
Jan 08, 2026, 5:22 PM EST
Filing Type: PRE 14A
Importance Score:
10
INDP
Jan 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8